Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program. This program can help to provide timely access to specialized care for adults living with ataxias — a group of neurological conditions characterized by progressive loss of coordination, balance, and motor function. Synapticure partnered with Biogen Inc. (Nasdaq: BIIB ) to support disease education and awareness efforts of this resource, helping to address a critical gap in access to care for the ataxia community. Biogen is not involved in developing, administering, or responsible for the Synapticure healthcare services, clinical considerations, or patient care. Adults with ataxias can receive specialized neurological care from Synapticure's care team or be co-managed alongside their existing care team. With this expansion, Synapticure adds to its comprehensive virtual platform for neurodegenerative care in the United States, now extending its reach to serve individuals living with ataxias across the country. "For people living with ataxias and their families, accessing expert neurological care is often a years-long struggle," said Sandra Abrevaya, CEO and Co-Founder of Synapticure. "Synapticure was built to change that dynamic — to expand access to specialized neurological expertise directly to patients where they live, and to make personalized, proactive care the standard rather than the exception. We are proud to now open our doors to the ataxia community." Ataxias affect tens of thousands of people in the United States 1 . With a growing landscape of disease-modifying research, the need for informed, ataxia-knowledgeable care has never been greater. "Highly specialized ataxia care and expertise can be difficult to find locally, posing a significant challenge for individuals and families," said Kristen Fortino, Head of the U.S. Rare Disease Franchise at Biogen. "Our commitment to people living with rare neurological diseases, including the broader ataxia community, extends beyond treatment. We are dedicated to providing meaningful support every step of the care journey including supporting greater awareness of available care resources." Synapticure's ataxia care program will be led by Dr. Elizabeth Ferluga, MD, Director of Movement Disorders at Synapticure, who brings deep clinical expertise in movement disorders and a longstanding commitment to rare neurological conditions. Dr. Ferluga and the Synapticure clinical team can provide patients with access to specialized evaluations, genetic counseling, and comprehensive longitudinal care — all delivered virtually by Synapticure's independent healthcare providers. "Patients with ataxias are a community that has been underserved by the traditional healthcare system for far too long," said Dr. Elizabeth Ferluga, MD, Director of Movement Disorders at Synapticure. "The Synapticure model is transformative for this population — we can meet patients where they are, perform a thorough evaluation, help them understand their diagnosis and what it means for them and their families, provide information about potential clinical trials, and be a consistent, knowledgeable partner in their care over time. I am incredibly excited to bring this level of support to the ataxia community." Synapticure's ataxia care program can provide patients with: Virtual medical evaluations with independent neurologists trained in movement disorders, including ataxias At-home genetic testing, where appropriate, including pre and post-test counseling by Synapticure's certified genetic counselors Coordinated evaluation of acquired causes of ataxias including comprehensive laboratory testing, brain imaging, and EMG/NCS ...